Australia Legal Cannabis Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Australia's legal cannabis market operates primarily through the federally regulated medical cannabis pathway administered by the Office of Drug Control and the Therapeutic Goods Administration, alongside state-level prescribing and dispensing frameworks. Independent commercial estimates place 2025 market value at roughly USD 862 million, though other published forecasts, such as those ranging from USD 126 million in 2024 toward USD 420 million by 2030, reflect narrower medical-only scopes. The discrepancy underscores that no official Australian statistical agency, including the Australian Bureau of Statistics or the Australian Institute of Health and Welfare, publishes an aggregated legal cannabis market revenue figure in dollars.

• •Medical cannabis and regulated hemp/CBD products are the core of Australia's legal market; recreational cannabis remains prohibited federally.
• •Independent estimates value the market at approximately USD 862 million in 2025, with a projected CAGR of about 16.19% through 2033.
• •The Australian Institute of Health and Welfare tracks cannabis use prevalence but does not publish a commercial market size figure in dollars.

Patient access has expanded steadily as the number of authorised prescribers and the volume of Special Access Scheme approvals issued through the TGA have grown each year. Schedule 3 down-scheduling of low-dose CBD in 2021 opened a pharmacist-only supply pathway, broadening consumer reach beyond prescription-only channels. Domestic cultivation licensing and cost-of-goods improvements, combined with growing export interest from Australian producers into European medical markets, are also lifting industry revenue.

• •Rising SAS Category B approvals and prescriber registrations are expanding the patient base for medicinal cannabis products.
• •Low-dose CBD availability as a pharmacist-only medicine is creating an over-the-counter consumer category.
• •Export-oriented cultivation by licensed producers is adding a second growth front beyond domestic demand.

The market is commonly segmented by product type (medical cannabis flower, oils, capsules, topicals), by compound profile (THC-dominant, CBD-dominant, balanced), and by end-use (chronic pain, mental health, oncology support, neurology). The medical cannabis sub-segment alone has been estimated at roughly USD 595 million in 2025, illustrating that prescription products form the majority of value. Activity is concentrated in jurisdictions with established prescribing frameworks such as Victoria, Queensland, New South Wales, Western Australia, and Tasmania, with Melbourne and Brisbane emerging as major hubs for cultivation and manufacturing.

• •Medical cannabis flower and oils dominate revenue, with CBD wellness products forming a faster-growing but smaller category.
• •Major cultivation and manufacturing clusters are located in Victoria, Queensland, New South Wales, Western Australia, and Tasmania.
• •Chronic pain, anxiety, and sleep disorders are the leading qualifying conditions driving prescription volume.

What are the recent trends and outlook?

Expectations centre on further regulatory refinement, particularly around pharmacist-led low-dose CBD supply and clearer advertising rules, alongside possible legislative reviews of broader cannabis frameworks. Producer focus is shifting toward pharmaceutical-grade formats, real-world evidence generation, and international export approvals to diversify revenue away from the domestic-only model. Should reform advance toward any adult-use pathway, upside scenarios in independent forecasts expand sharply, though current projections remain anchored to medical and wellness demand.

• •Pharmaceutical-grade product formats and clinical evidence are becoming core competitive differentiators.
• •Export approvals into European medical markets are a key revenue diversification strategy for Australian producers.
• •Any movement toward broader adult-use reform would materially lift longer-term forecast scenarios, though timelines remain uncertain.